Teledyne DALSA is a Canadian manufacturer of specialized electronic imaging components with offices in Montreal. The company is a leading manufacturer of heat (infrared) sensors for use in satellites, surveillance and medical applications — fields which attract extensive research and development investment from both government and industry.
Researchers like Yang Yang, a Mitacs Elevate postdoctoral fellow in the Pharmaceutical Orthopaedic Research lab at the University of Alberta, are tackling the problem head-on by developing new treatments for the disease. In partnership with Osteo-Metabolix Pharmaceuticals Inc., Yang has created a new drug that does a better job of healing broken bones.
When Calgary-based Chaordix, a pioneer in the crowdsourcing space, was looking to gain further insight into market research intelligence and analytics, they turned to Mitacs. We connected the company with intern Khobaib Zaamout, a PhD student in the department of Information and Communication Technology at the University of Calgary.
To meet its clients’ needs and an increasing demand for high-performance Automatic Speech Recognition (ASR) solutions, Nuance established a long-term research project that focuses on refining these products for mobile applications.
With the support of Pierre des Lierres, Business Development Director at Mitacs, the company obtained the financial support of Mitacs Accelerate Quebec and connected with Iban Harlouchet and Professor Pierre Lafaye de Micheaux from the Department of Mathematics and Statistics at Université de Montréal. Iban undertook research at Odotech to optimize algorithms of the e-nose sensors that analyze olfactory emissions.
By diagnosing oral premalignant lesions that might progress to cancer and making better clinical decisions, clinicians can significantly lower the mortality rate, increase quality of life with earlier and less traumatic surgery and reduce healthcare costs.
Toronto-based ProteoCyte Diagnostics Inc. developed a new diagnostic testing system, StraticyteTM, which can accurately and objectively identify premalignant oral lesions that have a high risk of becoming cancerous, allowing patients to undergo early treatment to ensure survival and improved quality of life.
Once prostate cancer is diagnosed, a series of biopsies has to be done to determine how serious the case is. These can be invasive and painful for the patient and may not give an accurate prognosis.
In partnership with Mitacs-Accelerate intern Julius Adebayo Awe, CancerCare Manitoba has developed an innovative way to determine the progression of prostate cancer in intermediate risk prostate cancer patients through a simple blood test. This work is done in collaboration with the Manitoba Prostate Centre and Drs. Darrel Drachenberg and Jeff Saranchuk.